Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 5/20 | 0.46 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.41 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.39 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31549660 | 1.00 | KDM4E (0.50) | KDM4ETSHRHPGDHSD17B10GAA | |
| SCHEMBL1781557 | 0.98 | KDM4E (0.52) | KDM4ETSHRHPGDHSD17B10GAA | |
| Bromide SCHEMBL20984459 | 0.95 | KDM4E (0.50) | KDM4ETSHRHPGDHSD17B10GAA | |
| Sulfuric Acid SCHEMBL20984556 | 0.86 | CA12 (0.49) | KDM4ETSHRHPGDHSD17B10GAA | |
| Oxalic Acid SCHEMBL20984729 | 0.86 | GAA (0.56) | KDM4ETSHRHPGDHSD17B10GAA | |
| Phosphoric Acid SCHEMBL20984128 | 0.86 | GAA (0.47) | KDM4ETSHRHPGDHSD17B10GAA | |
| Oxalic Acid SCHEMBL20984731 | 0.86 | GAA (0.56) | KDM4ETSHRHPGDHSD17B10GAA | |
| Nitric Acid SCHEMBL20984394 | 0.83 | GAA (0.45) | KDM4ETSHRHPGDHSD17B10GAA | |
| Hydrochloric Acid SCHEMBL20984076 | 0.81 | KDM4E (0.38) | KDM4ETSHRHPGDHSD17B10GAA | |
| Hydrochloric Acid SCHEMBL588029 | 0.79 | TSHR (0.42) | KDM4ETSHRHPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2021-06-22 | — | — | US | claimed |
| CN-107663161-B | Continuous flow synthesis process of phenylhydrazine salt and substituted phenylhydrazine salt | 上海惠和化德生物科技有限公司 | 2020-04-10 | — | — | CN | claimed |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2019-05-23 | — | — | US | claimed |
| CN-107540627-A | One kind has Tuo hydrogen Cong Suan oxadiazine Hete rocyclic derivatives of antibacterial activity and its production and use | 南京林业大学 | 2018-01-05 | — | — | CN | claimed |
| CN-117055658-B | Self-adaptive temperature control system and method for tiarelvone crystallization production process | 江苏徕德生物医药有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117055658-A | Self-adaptive temperature control system and method for tiarelvone crystallization production process | 江苏徕德生物医药有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2021-06-22 | — | — | US | disclosed |
| CN-107663161-B | Continuous flow synthesis process of phenylhydrazine salt and substituted phenylhydrazine salt | 上海惠和化德生物科技有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2019-05-23 | — | — | US | disclosed |
| CN-107739371-A | A kind of Tetrahydrocarbazolesand small molecular organic compounds and its purposes in antibacterials are prepared and preparation method thereof | 华东师范大学 | 2018-02-27 | — | — | CN | disclosed |
| CN-107663161-A | A kind of continuous stream synthesis technique of phenylhydrazine salt and substituted benzene hydrazonium salt | 上海惠和化德生物科技有限公司 | 2018-02-06 | — | — | CN | disclosed |
| CN-107540627-A | One kind has Tuo hydrogen Cong Suan oxadiazine Hete rocyclic derivatives of antibacterial activity and its production and use | 南京林业大学 | 2018-01-05 | — | — | CN | disclosed |
| US-7973036-B2 | 2-methyl-5-imino-benzo[D][1 ,3]oxazin[5-B]pyrazole compound, preparation and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD (CN) | 2011-07-05 | — | — | US | disclosed |
| US-20110118247-A1 | 2-Methyl-5-Imino-Benzo[D][1,3]Oxazin[5-B]Pyrazole Compound, Preparation and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2011-05-19 | — | — | US | disclosed |
| CN-101508696-B | 2-methyl-5-imidogen-benzo[d][1,3] oxazine[5-b] pyrazole compound, preparation method and application for preparing medicine thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO LTD | 2011-04-06 | — | — | CN | disclosed |
| CN-101830831-A | Method for preparing ortho-diazanyl benzonitrile | QINGDAO HUANGHAI PHARMACEUTICAL CO LTD | 2010-09-15 | — | — | CN | disclosed |
| CN-101508696-A | 2-methyl-5-imidogen-benzo[d][1,3] oxazine[5-b] pyrazole compound, preparation method and application thereof | QINGDAO HUANGHAI PHARMACEUTICA (CN) | 2009-08-19 | — | — | CN | disclosed |
| CN-101318968-A | Benzoxazine-pyrazoles and opened loop compound | QINGDAO HUANGHAI PHARMACEUTICA (CN) | 2008-12-10 | — | — | CN | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118247-A1 | 2-Methyl-5-Imino-Benzo[D][1,3]Oxazin[5-B]Pyrazole Compound, Preparation and Use Thereof | CYP3A5, CYP11B2, CYP4B1 | GAA 3936/4885GLA 3712/4885CA2 3592/4885 |
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | HPD, TYR, PDK2 | GAA 237/4885GLA 3304/4885CA2 931/4885 |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | HPD, TYR, PDK2 | GAA 237/4885GLA 3304/4885CA2 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.